Transonic Imaging | advancing breast screening
home,page-template,page-template-full_width,page-template-full_width-php,page,page-id-15250,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-10.1.1,wpb-js-composer js-comp-ver-5.0.1,vc_responsive

What is MUST?

In an MUST scan, a patient lies prone for 8 minutes with the breast immersed in a water with no contact or compression. While in the bath, the scan performs 3D tomography of pendulant breast using a transmission-mode ultrasound in a fixed-coordinate system at each tissue voxel.

The MUST scan achieves automated lesion differentiation via the proper combination of refractivity and attenuation measurements, offering the physician easy and reliable detection of malignant lesions in 3D to be used in conjunction with conventional mammograms and ultrasound.

The scan uses two parallel transducer plates mechanically sweeping in the direction of the long axis and the Sonobra allows for comfort for different sized breasts.

The coronal slice of the MUST scan show colorful and automated lesion differentiation via the proper combination of refractivity and attenuation measurements.

The cornonal composite Images clearly depict lesions in red as having high composite index values. The MUST system is designed to for reliable detection of malignant lesions in 3D (down to 4 mm).

MUST Technology (Summary Principle of Transonic Tomography)

Current mammogram practices density cluster of micro-calcifications as indirect marker of possible malignant lesion in the vicinity.

Patient is classified as BIRADS-4 and referred to biopsy.

3D display of 15 MUT slice images

Transmission-mode ultrasound scan of whole breast generates 3D tomographic images using attenuation & refractivity measurements at each tissue voxel.

Water-through pulse transmission

Diagnostic images are computed from the recorded data using proprietary algorithms. Tumors are identified quantitatively (using a Composite Index) by their elevated hardness & viscosity (Stokes Law) and plotted in 3D color-metrically, facilitating clinical workflow.

Tissue-through pulse transmission

Utilize changes in breast-traversing US pulse waveform & travel time (attenuation and refractivity of tissue voxels).

Clinical Studies

Clinical trial of MUST is planned for mid-2017 when we will compare sensitivity results from 3D Mammogram alone vs 3D mammogram plus MUST in 6,000 women at 4 major European hospitals.


Clinical Results from 524 Biopsy-Confirmed Cases


• 524 cases were categorized as BIRADS 3,4 or 5 at two major hospitals in Athens and sent to biopsy


• 167 were confirmed positive by biopsy, of which 163 (98% sensitivity) were also confirmed positive by MUST (missing only 4 DCIS < 4 mm)


• 357 were confirmed negative by biopsy, of which 335 were also independently confirmed negative by MUST (94% specificity)


The Company was founded by Professor Vasilis Marmarelis of USC, a well known expert in the field of Bioengineering. The preclinical research was funded by the Alfred Mann Institute (“AMI”) at USC and further clinical research was funded through a European Union Grant and Private European Investors.
Michael Sofras Bio Picture
Michael Sofras, President & CTO of Transonic Imaging Inc., developed and tested the MUST clinical prototypes in collaboration with the inventor, Prof. Marmarelis. He has managed all clinical trials of MUST and has served as CEO of Mastoscopia S.A., the wholly-owned European subsidiary that developed and tested the MUST technology.